PRAETORIAN-XL study shows a significantly lower risk of severe complications for patients with a subcutaneous ICDThe results of the PRAETORIAN-XL were presented as a late breaking trial at the Heart Rhythm 2025 conference in San Diego. In the study, 849 patients in 39 hospitals in Europe and the US were randomized between two types of ICD; the subcutaneous and the transvenous ICD. These patients were followed for more than 7 years, which showed a significantly lower risk in severe complications for patients with a subcutaneous ICD. The study was fully executed by Amsterdam UMC.